Press release
Sandhoff Disease Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Discover the latest drugs and treatment options in the Sandhoff Disease Pipeline. Dive into DelveInsight's comprehensive report today! @ Sandhoff Disease Pipeline Outlook [https://www.delveinsight.com/sample-request/sandhoff-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Sandhoff Disease Pipeline Report
* DelveInsight's Sandhoff Disease Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Sandhoff Disease treatment.
* The leading Sandhoff Disease Companies such as IntraBio, Sanofi, Polaryx Therapeutics, Azafaros and others.
* Promising Sandhoff Disease Pipeline Therapies such as IB1001, Zavesca (Miglustat), TSHA-101, Miglustat and others.
Stay ahead with the most recent pipeline outlook for Sandhoff Disease. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Sandhoff Disease Treatment Drugs [https://www.delveinsight.com/sample-request/sandhoff-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Sandhoff Disease Emerging Drugs Profile
* IB1001: IntraBio
IB1001, N-acetyl-L-leucine, is an orally administered modified amino acid. In vivo studies have identified N-acetyl-L-leucine to be the active isomer of N-acetyl-DL-leucine and can restore neuronal function and protect against/delay disease progression in multiple neurological circuits of the brain. The mechanism of N-acetyl-L-leucine is known to be multi-modal, including altered glucose and antioxidant metabolism, reduced lysosomal storage, and the reduction of neuroinflammation in the cerebellum, leading to the attenuation of cell death. The company is conducting a multinational, multicenter, open-label, rater-blinded prospective Phase II study which will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease).
* Venglustat: Sanofi
Venglustat is a novel, oral investigational therapy that has the potential to slow the progression of certain diseases by inhibiting abnormal glycosphingolipid (GSL) accumulation. GSLs are cellular building blocks whose abnormal accumulation is implicated in several rare diseases, responsible for both cell dysfunction and disease progression.Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Sandhoff Disease.
The Sandhoff Disease Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Sandhoff Disease with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sandhoff Disease Treatment.
* Sandhoff Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Sandhoff Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sandhoff Disease market
Explore groundbreaking therapies and clinical trials in the Sandhoff Disease Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Sandhoff Disease Drugs [https://www.delveinsight.com/sample-request/sandhoff-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Sandhoff Disease Companies
IntraBio, Sanofi, Polaryx Therapeutics, Azafaros and others.
Sandhoff disease Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
Sandhoff Disease Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Unveil the future of Sandhoff Disease Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Sandhoff Disease Market Drivers and Barriers [https://www.delveinsight.com/sample-request/sandhoff-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Sandhoff Disease Pipeline Report
* Coverage- Global
* Sandhoff Disease Companies- IntraBio, Sanofi, Polaryx Therapeutics, Azafaros and others.
* Sandhoff Disease Pipeline Therapies- IB1001, Zavesca (Miglustat), TSHA-101, Miglustat and others.
* Sandhoff Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Sandhoff Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Sandhoff Disease Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Sandhoff Disease Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/sandhoff-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Sandhoff disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Sandhoff disease - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Venglustat: Sanofi
* Drug profiles in the detailed report.....
* Mid-Stage Products (Phase II)
* IB1001: IntraBio
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Sandhoff disease Key Companies
* Sandhoff disease Key Products
* Sandhoff disease- Unmet Needs
* Sandhoff disease- Market Drivers and Barriers
* Sandhoff disease- Future Perspectives and Conclusion
* Sandhoff disease Analyst Views
* Sandhoff disease Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=sandhoff-disease-pipeline-appears-robust-with-5-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/sandhoff-disease-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Sandhoff Disease Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4026997 • Views: …
More Releases from ABNewswire
The End of the Generic Bot: Rankified.AI Brings "Trainable" AI Technology to Loc …
RIDGEWOOD, NJ - Local businesses have long been stuck between two bad options: expensive marketing agencies or cheap, robotic-sounding AI tools. Today, Rankified.AI bridges that gap by deploying the first "Trainable" Local Growth Engine specifically designed for Main Street businesses.
Unlike standard "ChatGPT wrappers" that generate generic content, Rankified.AI [http://rankified.ai] leverages advanced generative models that business owners can actually train. By inputting their specific "Business DNA"-services, tone, and offers-users create a…
Hire Programmers/Developers (Onsite/Remote) - Develop Project, Product or MVP
Hiring top developers through PROVAB, will ensure that you get a professional with proven delivery records. Our flexible hiring models will give you the ability to directly communicate with your developer, assign work and monitor the overall progress. We help you quickly ramp up your team, launching / managing your web or mobile application.
Accelerate your digital initiatives with expert software engineering teams. A recent market research on the global offshoring…
New Jersey Criminal Defense Attorney Adam M. Lustberg Explains What Jury Nullifi …
Hackensack, New Jersey - New Jersey criminal defense attorney Adam M. Lustberg of Lustberg Law Offices LLC (https://www.lustberglaw.com/blog/what-is-jury-nullification/) is highlighting the legal and practical implications of jury nullification for individuals facing criminal charges in Bergen County and throughout New Jersey. Jury nullification arises when a jury returns a not guilty verdict even though the evidence supports each element of the offense, because jurors believe that the law itself is unjust…
Manhattan Real Estate Attorney Peter Zinkovetsky Provides Guidance On Apartment …
New York, NY - Peter Zinkovetsky, Esq., a leading Manhattan real estate attorney and founder and Managing Partner of Avenue Law Firm (https://www.avenuelawfirm.com/what-to-do-in-an-apartment-lease-buyout/), is offering in-depth guidance to New York City tenants facing apartment lease buyout offers in one of the nation's most competitive rental markets. As redevelopment projects and rising market rents reshape neighborhoods from Midtown to Tribeca and the Upper West Side, the firm is focused on helping…
More Releases for Sandhoff
Sandhoff Disease Market to Reach USD 72.4 Million by 2034 Driven
Pune, India - December 2025 - The global Sandhoff Disease Market, valued at USD 29.6 million in 2024, is expected to reach USD 72.4 million by 2034, growing at a 9.4% CAGR (2025-2034), according to Exactitude Consultancy. Market growth is driven by increasing R&D in rare neurodegenerative disorders, rising investment in gene therapy, and supportive regulatory incentives for orphan drug development.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/72045
Market Summary
The…
Sandhoff Disease Market to Reach USD 1.2 Billion by 2034
Sandhoff disease is a rare, inherited lysosomal storage disorder caused by mutations in the HEXB gene, leading to a deficiency in the beta-hexosaminidase A and B enzymes. This deficiency results in the accumulation of GM2 gangliosides within nerve cells, causing progressive neurodegeneration. Sandhoff disease presents in various forms-infantile, juvenile, and adult-onset-with the infantile type being the most severe and often fatal by early childhood.
Download Full PDF Sample Copy of Market…
Sandhoff Disease Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Sandhoff Disease Pipeline Insight 2025" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Sandhoff Disease pipeline landscape. It covers the Sandhoff Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sandhoff Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Sandhoff Disease pipeline products in this space.
Discover the latest drugs…
Sandhoff Disease Market Size, Share, Trends, Growth 2024-2032
The Sandhoff disease market size was valued at USD 10.18 billion in 2023, driven growing interest in gene therapy as a potential curative approach across the major markets. The market size is anticipated to grow at a CAGR of 5.87% during the forecast period of 2024-2032 and attain a value of USD 17 billion by 2032.
Sandhoff Disease:
Sandhoff disease is a rare, inherited genetic disorder characterized by the harmful accumulation of…
Sandhoff Disease Treatment Market Analysis: Understanding Trends, Players, and P …
"Sandhoff Disease Treatment Market Is Growing At A Steady Cagr During Forecast Period".
With thorough company profiles, recent developments, and other information, the Sandhoff Disease Treatment Market Report provides an in-depth analysis of major trends, motivating reasons, obstacles, segmentation, regulatory policies, and important players. The Sandhoff Disease Treatment Market Report offers a thorough synopsis of the product portfolio, including product development, planning, and positioning of products with emerging technologies, impending opportunities,…
Sandhoff Disease Market: Analysis of Epidemiology, Industry Trends, Size, Share, …
IMARC Group has recently released a report titled "Sandhoff Disease Market : Analysis of Epidemiology, Industry Trends, Size, Share, and Future Forecast (2023-2033)" that presents a comprehensive assessment of the sandhoff disease market size . The report provides an extensive overview of the latest market trends, growth prospects, investment opportunities, and industry outlook, as well as an in-depth analysis of the disease landscape, market size, and growth trends. Furthermore, the…
